[{"id":"300dc214-2f53-46f4-88db-099cbeecb27f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05755087","created_at":"2023-03-06T15:01:37.165Z","updated_at":"2024-07-02T16:35:24.905Z","phase":"Phase 1","brief_title":"Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma","source_id_and_acronym":"NCT05755087","lead_sponsor":"Lapo Alinari","biomarkers":" MYC • BCL2 • BCL6","pipe":" | ","alterations":" BCL2 expression • MYC expression • MYC translocation • MYC translocation + BCL2 translocation • BCL2 translocation","tags":["MYC • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • MYC expression • MYC translocation • MYC translocation + BCL2 translocation • BCL2 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tegavivint (BC2059)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 03/06/2023","start_date":" 03/06/2023","primary_txt":" Primary completion: 03/05/2027","primary_completion_date":" 03/05/2027","study_txt":" Completion: 03/05/2027","study_completion_date":" 03/05/2027","last_update_posted":"2023-12-29"}]